Literature DB >> 21448875

Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer.

Regine M Schoenherr1, Karen S Kelly-Spratt, ChenWei Lin, Jeffrey R Whiteaker, Tao Liu, Ted Holzman, Ilsa Coleman, Li-Chia Feng, Travis D Lorentzen, Alexei L Krasnoselsky, Pei Wang, Yan Liu, Kay E Gurley, Lynn M Amon, Athena A Schepmoes, Ronald J Moore, David G Camp, Lewis A Chodosh, Richard D Smith, Peter S Nelson, Martin W McIntosh, Christopher J Kemp, Amanda G Paulovich.   

Abstract

PURPOSE: We generated extensive transcriptional and proteomic profiles from a Her2-driven mouse model of breast cancer that closely recapitulates human breast cancer. This report makes these data publicly available in raw and processed forms, as a resource to the community. Importantly, we previously made biospecimens from this same mouse model freely available through a sample repository, so researchers can obtain samples to test biological hypotheses without the need of breeding animals and collecting biospecimens. EXPERIMENTAL
DESIGN: Twelve datasets are available, encompassing 841 LC-MS/MS experiments (plasma and tissues) and 255 microarray analyses of multiple tissues (thymus, spleen, liver, blood cells, and breast). Cases and controls were rigorously paired to avoid bias.
RESULTS: In total, 18,880 unique peptides were identified (PeptideProphet peptide error rate ≤1%), with 3884 and 1659 non-redundant protein groups identified in plasma and tissue datasets, respectively. Sixty-one of these protein groups overlapped between cancer plasma and cancer tissue. CONCLUSIONS AND CLINICAL RELEVANCE: These data are of use for advancing our understanding of cancer biology, for software and quality control tool development, investigations of analytical variation in MS/MS data, and selection of proteotypic peptides for multiple reaction monitoring-MS. The availability of these datasets will contribute positively to clinical proteomics.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21448875      PMCID: PMC3069718          DOI: 10.1002/prca.201000037

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  35 in total

1.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search.

Authors:  Andrew Keller; Alexey I Nesvizhskii; Eugene Kolker; Ruedi Aebersold
Journal:  Anal Chem       Date:  2002-10-15       Impact factor: 6.986

2.  TANDEM: matching proteins with tandem mass spectra.

Authors:  Robertson Craig; Ronald C Beavis
Journal:  Bioinformatics       Date:  2004-02-19       Impact factor: 6.937

3.  Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein.

Authors:  Yasushi Ishihama; Yoshiya Oda; Tsuyoshi Tabata; Toshitaka Sato; Takeshi Nagasu; Juri Rappsilber; Matthias Mann
Journal:  Mol Cell Proteomics       Date:  2005-06-14       Impact factor: 5.911

4.  Halogenated peptides as internal standards (H-PINS): introduction of an MS-based internal standard set for liquid chromatography-mass spectrometry.

Authors:  Hamid Mirzaei; Mi-Youn Brusniak; Lukas N Mueller; Simon Letarte; Julian D Watts; Ruedi Aebersold
Journal:  Mol Cell Proteomics       Date:  2009-05-01       Impact factor: 5.911

5.  Characterization of the mouse pancreatic islet proteome and comparative analysis with other mouse tissues.

Authors:  Vladislav A Petyuk; Wei-Jun Qian; Charlotte Hinault; Marina A Gritsenko; Mudita Singhal; Matthew E Monroe; David G Camp; Rohit N Kulkarni; Richard D Smith
Journal:  J Proteome Res       Date:  2008-06-21       Impact factor: 4.466

6.  Clinical proteomics: A need to define the field and to begin to set adequate standards.

Authors:  Harald Mischak; Rolf Apweiler; Rosamonde E Banks; Mark Conaway; Joshua Coon; Anna Dominiczak; Jochen H H Ehrich; Danilo Fliser; Mark Girolami; Henning Hermjakob; Denis Hochstrasser; Joachim Jankowski; Bruce A Julian; Walter Kolch; Ziad A Massy; Christian Neusuess; Jan Novak; Karlheinz Peter; Kasper Rossing; Joost Schanstra; O John Semmes; Dan Theodorescu; Visith Thongboonkerd; Eva M Weissinger; Jennifer E Van Eyk; Tadashi Yamamoto
Journal:  Proteomics Clin Appl       Date:  2007-01-22       Impact factor: 3.494

7.  Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution.

Authors:  Hasmik Keshishian; Terri Addona; Michael Burgess; D R Mani; Xu Shi; Eric Kuhn; Marc S Sabatine; Robert E Gerszten; Steven A Carr
Journal:  Mol Cell Proteomics       Date:  2009-07-13       Impact factor: 5.911

Review 8.  Maximizing mouse cancer models.

Authors:  Kristopher K Frese; David A Tuveson
Journal:  Nat Rev Cancer       Date:  2007-09       Impact factor: 60.716

Review 9.  ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas.

Authors:  Elena Quaglino; Cristina Mastini; Guido Forni; Federica Cavallo
Journal:  Curr Protoc Immunol       Date:  2008-08

10.  MRM screening/biomarker discovery with linear ion trap MS: a library of human cancer-specific peptides.

Authors:  Xu Yang; Iulia M Lazar
Journal:  BMC Cancer       Date:  2009-03-27       Impact factor: 4.430

View more
  8 in total

Review 1.  How to Choose a Mouse Model of Breast Cancer, a Genomic Perspective.

Authors:  Matthew R Swiatnicki; Eran R Andrechek
Journal:  J Mammary Gland Biol Neoplasia       Date:  2019-06-21       Impact factor: 2.673

2.  Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression.

Authors:  Sharon J Pitteri; Karen S Kelly-Spratt; Kay E Gurley; Jacob Kennedy; Tina Busald Buson; Alice Chin; Hong Wang; Qing Zhang; Chee-Hong Wong; Lewis A Chodosh; Peter S Nelson; Samir M Hanash; Christopher J Kemp
Journal:  Cancer Res       Date:  2011-06-08       Impact factor: 12.701

3.  Synthesis and evaluation of 18F labeled alanine derivatives as potential tumor imaging agents.

Authors:  Limin Wang; Zhihao Zha; Wenchao Qu; Hongwen Qiao; Brian P Lieberman; Karl Plössl; Hank F Kung
Journal:  Nucl Med Biol       Date:  2012-04-26       Impact factor: 2.408

Review 4.  Genetically engineered mice as experimental tools to dissect the critical events in breast cancer.

Authors:  Mitchell E Menezes; Swadesh K Das; Luni Emdad; Jolene J Windle; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

Review 5.  An assessment of current bioinformatic solutions for analyzing LC-MS data acquired by selected reaction monitoring technology.

Authors:  Mi-Youn K Brusniak; Caroline S Chu; Ulrike Kusebauch; Mark J Sartain; Julian D Watts; Robert L Moritz
Journal:  Proteomics       Date:  2012-04       Impact factor: 3.984

6.  A targeted proteomics-based pipeline for verification of biomarkers in plasma.

Authors:  Jeffrey R Whiteaker; Chenwei Lin; Jacob Kennedy; Liming Hou; Mary Trute; Izabela Sokal; Ping Yan; Regine M Schoenherr; Lei Zhao; Uliana J Voytovich; Karen S Kelly-Spratt; Alexei Krasnoselsky; Philip R Gafken; Jason M Hogan; Lisa A Jones; Pei Wang; Lynn Amon; Lewis A Chodosh; Peter S Nelson; Martin W McIntosh; Christopher J Kemp; Amanda G Paulovich
Journal:  Nat Biotechnol       Date:  2011-06-19       Impact factor: 54.908

7.  A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer.

Authors:  Daniel P Hollern; Eran R Andrechek
Journal:  Breast Cancer Res       Date:  2014-06-05       Impact factor: 6.466

8.  Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes.

Authors:  Marta Dueñas; Mirentxu Santos; Juan F Aranda; Concha Bielza; Ana B Martínez-Cruz; Corina Lorz; Miquel Taron; Eva M Ciruelos; José L Rodríguez-Peralto; Miguel Martín; Pedro Larrañaga; Jubrail Dahabreh; George P Stathopoulos; Rafael Rosell; Jesús M Paramio; Ramón García-Escudero
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.